CME: Ulcerative Colitis (UC): Therapeutic Updates, Best Practices, and Barriers to Care
ACCREDITATION EXPIRED: January 22, 2016
Activity Description / Statement of Need:
In this online CME self-learning program:
Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease, the former of which exclusively affects the colon and rectum. Guidelines exist for the treatment of UC, but they are constantly changing to include updated information. The World Gastroenterology Organization, for example, published updated practice guidelines in 2009 for IBD including extensive diagnosis and treatment criteria, and the American College of Gastroenterology published updated practice guidelines in 2010 for UC.
A more specific area of UC treatment that merits focus is the increased risk of metabolic bone disease, such as osteoporosis, that patients with UC experience. Slightly less than half of doctors surveyed in one study used the American Gastroenterology Association Guidelines on Osteoporosis in Inflammatory Disease Patients. Also, among the gastroenterologists who claimed to follow these guidelines, the majority still reported that they referred the patient back to his or her primary care physician instead of treating the patient themselves. These guidelines would ideally be followed by all health care providers, specialist or not.
Agenda:
Introduction, Disclosures
Diagnosis and initial evaluation of UC
• UC epidemiology and pathophysiology
• Risk factors and disease complications
• Making the diagnosis and clinical pearls for the initial visit
Inducing and maintaining remission
• Management of mild-to-moderate, active disease
• Maintenance of remission in mild-to-moderate disease
• Management of severe UC
Prevention of complications associated with UC
• Colorectal cancer surveillance
• Bone health
• Vaccinations
• Venous thromboembolism
• Barriers to adherence to therapy
Target Audience:
Healthcare professionals specializing in: endocrinology, family medicine, gastroenterology, internal medicine, surgery, or those who otherwise commonly care for patients with UC.
This program is supported by educational grants from SHIRE and from Valeant Pharmaceuticals.
Release Date: January 22, 2014 -- Expiration Date: January 22, 2016
Faculty: Seymour Katz, MD -- Lea Ann Chen, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Describe appropriate testing for the diagnosis and management of UC.
- Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
- Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety and efficacy, suggesting modifications for improvement.
- Identify ways to optimize preventive care in patients with UC.
- Describe barriers to care in the treatment of UC
Accreditation
THIS COURSE IS EXPIRED. NO CREDIT WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosures:
Seymour Katz, MD, has received grant funding and/or consulting income and/or speaker's bureau income from Warner-Chilcott, UCB, Abbott, BMS, Centocor, Forest Laboratories, GSK, Hutchison, Millenium, Pfizer, Prometheus, Quest, and Shire Pharmaceuticals.
Lea Ann Chen, MD, discloses that she is a stockholder of the following companies: Bristol-Myers Squibb, Organovo, and Pfizer.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by educational grants from SHIRE and from Valeant Pharmaceuticals.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.